<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9630">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05694013</url>
  </required_header>
  <id_info>
    <org_study_id>MO42720</org_study_id>
    <nct_id>NCT05694013</nct_id>
  </id_info>
  <brief_title>Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice</brief_title>
  <acronym>ORIGAMA</acronym>
  <official_title>Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization in Participants Receiving Systemic Treatment in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical impact and utility of digital health solutions (DHS) on&#xD;
      health outcomes and health-care resource utilization in people receiving systemic anti-cancer&#xD;
      treatment (approved or non-approved) in clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2023</start_date>
  <completion_date type="Anticipated">July 7, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in change of Week 12 value from baseline of participant-reported Total Symptom Interference Score from the MD Anderson Symptom Inventory (MDASI) Core Items (Cohort A)</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with Flexcare adoption at Cycle 6 (Cohort B)</measure>
    <time_frame>Cycle 6 (cycle length = 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations due to serious adverse events (SAEs) (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cumulative days hospitalized due to SAEs (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unscheduled visits to the emergency room (ER) or clinic for symptom management (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Global Health Status score/Quality of Life score (GHS/QoL) from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library 6 (IL6) GHS/QoL (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQol EQ-5D-5L index-based instrument (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQol EQ-5D-5L Visual Analogue Scale (VAS) instrument (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean symptom severity score from the MDASI Core Items (Cohort A)</measure>
    <time_frame>Up to approximately 28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic non-small cell lung carcinoma (mNSCLC), extensive-stage small-cell lung carcinoma (ES-SCLC), and advanced or unresectable hepatocellular carcinoma (HCC) and who are prescribed an anticancer regimen including intravenous (IV) atezolizumab will use the Roche Digital Patient Monitoring (DPM) Module along with local standard of care (SOC) support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mNSCLC, ES-SCLC, and HCC who are prescribed an anticancer regimen including IV atezolizumab will receive local SOC support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with resected Stage IIB-IIIB NSCLC will use the Roche DPM Module along with subcutaneous (SC) atezolizumab in both the hospital and flexcare (home) setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Roche DPM Module</intervention_name>
    <description>Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support</description>
    <arm_group_label>Cohort A - Arm 1</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab SC</intervention_name>
    <description>Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Local SOC support</intervention_name>
    <description>Participants will receive local SOC support</description>
    <arm_group_label>Cohort A - Arm 1</arm_group_label>
    <arm_group_label>Cohort A - Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All Participants&#xD;
&#xD;
          -  Email address, access to an internet-capable device (smartphone, tablet, or PC), and&#xD;
             access to an internet connection&#xD;
&#xD;
        Inclusion Criteria: Cohort A&#xD;
&#xD;
          -  Histologically confirmed diagnosis for mNSCLC, ES-SCLC, or HCC (Child Pugh A)&#xD;
&#xD;
          -  Systemic therapy naive&#xD;
&#xD;
          -  Prescribed an atezolizumab IV regimen&#xD;
&#xD;
          -  Easter Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2&#xD;
&#xD;
        Inclusion Criteria: Cohort B&#xD;
&#xD;
          -  Complete resection of a histologically or cytologically confirmed Stage IIB-IIIB&#xD;
             (T3-N2) NSCLC&#xD;
&#xD;
          -  PD-L1 positive&#xD;
&#xD;
          -  Have completed adjuvant chemotherapy at least 4 weeks and up to 12 weeks prior to&#xD;
             randomization and must be adequately recovered from chemotherapy treatment&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  For participants receiving therapeutic anticoagulation: stable anticoagulant regimen&#xD;
&#xD;
          -  Negative for hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
        Exclusion Criteria: All Participants&#xD;
&#xD;
          -  Any physical or cognitive condition that would prevent the participant from using the&#xD;
             DHS&#xD;
&#xD;
          -  Participants not proficient with any of the available DHS language translations or&#xD;
             with psychiatric/neurologic disorders or any condition that may impact the&#xD;
             participant's ability to use the DPM solution&#xD;
&#xD;
          -  Currently participating in another interventional trial&#xD;
&#xD;
          -  History of malignancy within 5 years prior to initiation of study treatment, with the&#xD;
             exception of the cancer under investigation in this study and malignancies with a&#xD;
             negligible risk of metastasis or death&#xD;
&#xD;
        Exclusion Criteria: Cohort A&#xD;
&#xD;
          -  Concomitant anti-cancer therapy at the time of starting atezolizumab (IV) regimen on&#xD;
             the index date which is not part of a locally approved combination therapy with&#xD;
             atezolizumab&#xD;
&#xD;
          -  Participants not receiving atezolizumab, but an atezolizumab biosimilar or&#xD;
             non-comparable biologic&#xD;
&#xD;
          -  Participants currently using another DPM or ePRO solution for symptom management&#xD;
             and/or reporting&#xD;
&#xD;
        Exclusion Criteria: Cohort B&#xD;
&#xD;
          -  Participants known to have a sensitizing mutation in the EGFR gene or an ALK fusion&#xD;
             oncogene&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently)&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation&#xD;
             of study treatment, or anticipation of need for a major surgical procedure during the&#xD;
             study&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment, including, but&#xD;
             not limited to, hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia, or any active infection that could impact participant safety&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation&#xD;
             of study treatment&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             treatment, or anticipation of need for such a vaccine during atezolizumab treatment or&#xD;
             within 5 months after the final dose of atezolizumab&#xD;
&#xD;
          -  Current treatment with anti-viral therapy for HBV&#xD;
&#xD;
          -  Treatment with investigational therapy within 28 days prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including&#xD;
             anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including, but not limited to,&#xD;
             interferon and IL-2) within 4 weeks or 5 drug elimination half-lives (whichever is&#xD;
             longer) prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-tumor necrosis factor-α [TNF-α] agents) within 2 weeks prior to initiation of&#xD;
             study treatment, or anticipation of need for systemic immunosuppressive medication&#xD;
             during study treatment&#xD;
&#xD;
          -  History of severe allergic anaphylactic reactions to chimeric or humanized antibodies&#xD;
             or fusion proteins&#xD;
&#xD;
          -  Known hypersensitivity to Chinese hamster ovary cell products or to any component of&#xD;
             the atezolizumab formulation&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Known allergy or hypersensitivity to hyaluronidase, bee or vespid venom, or any other&#xD;
             ingredient in the formulation of rHuPH20&#xD;
&#xD;
          -  Pathology (e.g., lower extremity edema, cellulitis, lymphatic disorder or prior&#xD;
             surgery, preexisting pain syndrome, previous lymph node dissection, etc.) that could&#xD;
             interfere with any protocol-specified outcome assessment&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation, or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for ≥ 2 weeks prior to randomization&#xD;
&#xD;
          -  Participants currently using another DPM or ePRO solution for symptom management&#xD;
             and/or reporting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-LaRoche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: MO42720 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital; The Adem Crosby Centre</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Latrobe Regional Hospital</name>
      <address>
        <city>Traralgon</city>
        <state>Victoria</state>
        <zip>3844</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lkh-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer; Servicio de Oncologia</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Hematología y Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia; Servicio de oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet; Servicio Oncologia</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>December 20, 2022</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>May 24, 2023</last_update_submitted>
  <last_update_submitted_qc>May 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remote Patient Monitoring, Digital Patient Monitoring, Symptom Monitoring, Digital Health</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

